<DOC>
	<DOCNO>NCT02285114</DOCNO>
	<brief_summary>This study evaluate pharmacokinetics ( PK ) , safety , efficacy emtricitabine/tenofovir alafenamide ( F/TAF ) HIV-1 infected child adolescent virologically suppress ( define &lt; 50 copies/mL HIV-1 RNA period least 6 month ) stable 2-nucleoside/nucleotide reverse transcriptase inhibitor ( NRTI ) contain regimen .</brief_summary>
	<brief_title>Emtricitabine/Tenofovir Alafenamide ( F/TAF ) HIV-1 Infected Children Adolescents Virologically Suppressed 2-NRTI-Containing Regimen</brief_title>
	<detailed_description>There 2 Cohorts study . Cohort 1 ( adolescent 12 &lt; 18 year ) non-randomized participant switch current 2-NRTI contain regimen F/TAF continue 3rd antiretroviral ( ARV ) agent 96 week . Upon review safety PK data Cohort 1 , screen Part A Cohort 2 initiate . Cohort 2 ( child 6 &lt; 12 year ) randomize consist Parts A B . Participants Cohort 2 Part A randomize receive either F/TAF emtricitabine/tenofovir disoproxil fumarate ( FTC/TDF ) continue 3rd ARV agent 96 week . Upon review safety intensive PK data Cohort 2 Part A , screen Cohort 2 Part B initiate . Participants Cohort 2 Part B randomize receive either F/TAF FTC/TDF continue 3rd ARV agent 96 week .</detailed_description>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>HIV1 infect male female adolescent child age 6 &lt; 18 year baseline/Day 1 ( accord requirement enrol cohort ) Must able give write assent prior screen evaluation Parent guardian able give write informed consent prior screen evaluation willing comply study requirement Body weight screen follow : Cohort 1 : ≥ 35 kg Cohort 2 : ≥ 14 kg Currently stable 2NRTI contain regimen include 3rd ARV agent ≥ 6 consecutive month prior screen Plasma HIV1 RNA level &lt; 50 copies/mL ≥ 6 consecutive month precede screen visit No opportunistic infection within 30 day study entry ( baseline/Day 1 ) A negative serum βhuman chorionic gonadotropin ( HCG ) pregnancy test require female childbearing potential An acquired immunodeficiency syndrome ( AIDS ) indicator condition onset within 30 day prior screen Life expectancy &lt; 2 year Active , serious infection ( HIV1 infection ) require parenteral antibiotic antifungal therapy within 30 day prior baseline/Day 1 Evidence active pulmonary extrapulmonary tuberculosis disease within 3 month screen visit Active hepatitis C virus ( HCV ) infection define positive HCV antibody detectable HCV RNA Positive hepatitis B surface antigen evidence active hepatitis B virus ( HBV ) infection . Have serious active medical psychiatric illness , opinion Investigator , would interfere treatment , assessment , compliance protocol . Pregnant lactating female Have history significant drug sensitivity drug allergy Have previously participate investigational trial involve administration investigational agent , tenofovir , within 30 day prior study dose</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>emtricitabine</keyword>
	<keyword>FTC</keyword>
	<keyword>tenofovir</keyword>
	<keyword>TDF</keyword>
	<keyword>TAF</keyword>
	<keyword>antiretroviral</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>PK</keyword>
	<keyword>adolescent</keyword>
	<keyword>child</keyword>
	<keyword>pediatric</keyword>
	<keyword>Gilead</keyword>
</DOC>